Gastrointestinal Cancer, Metastatic
Conditions
Brief summary
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with chemotherapy and bevacizumab. The purpose of the first part is to find the highest BI 905711 dose participants can tolerate. In the second part, participants with colorectal cancer or pancreatic cancer get BI 905711 combined with chemotherapy. Some participants also get bevacizumab. The second part tests whether BI 905711 makes tumours shrink. Participants get BI 905711, chemotherapy and bevacizumab about every 2 weeks as an infusion into a vein. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors regularly check the health of the participants and note any health problems that could have been caused by the study treatment. The doctors also monitor the size of the tumour.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1a non randomized, Phase 1b randomized.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed and dated written informed consent in accordance with International Council of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. * Of legal adult age (according to local legislation) at screening. * Histologically or cytologically confirmed, advanced unresectable or metastatic colorectal adenocarcinoma. * Colorectal adenocarcinoma (CRC): Patients who have Progressive disease (PD) after prior oxaliplatin-based first line therapy or within 6 months after the end of oxaliplatin-based adjuvant therapy. * Eastern Cooperative Oncology Group (ECOG) performance status ≤1. * Life expectancy ≥ 3 months in the opinion of the investigator. * Availability and willingness to provide tumor tissue (fresh biopsy or archival) for biomarker analysis. Only non-significant risk procedures per the investigator's judgment will be used to obtain any biopsies specified in this study. In case a fresh tumor biopsy cannot be obtained, the recruitment of the patient may proceed on a case-by-case basis after agreement between the investigator and BI. In such a case, an archived tumor tissue specimen must be submitted. * Adequate hepatic, pancreatic, renal and bone marrow functions as defined by all of the below: * Total bilirubin ≤ 1.5 x institutional upper level of normal (ULN). * Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤2.5 x institutional ULN or ≤5 x institutional ULN for patients with known liver metastases. * Serum creatinine ≤1.5x institutional ULN. If creatinine is \> 1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥ 50 ml/min (≥ 0.05L/min) (measured or calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or Japanese version of CKD-EPI formula for Japanese patients). * Absolute neutrophil count (ANC) ≥ 1.5 x 1\^9/L, ≥ 1.5 x 10\^3/μL, or ≥ 1500/mm\^3 * Platelets ≥ 100 x 10\^9/L, ≥ 100 x 10\^3/μL, or ≥ 100 x 10\^3/mm\^3 * Hemoglobin (Hb) ≥ 8.5 g/dl, ≥ 85 g/L, or ≥ 5.3 mmol/L (without transfusion within previous week) Serum lipase ≤ 1.5 institutional ULN (Only for CRC cohort); \>1.5 - 2.0 x ULN or asymptomatic \>2.0 - 5.0 x ULN if related to Pancreatic Ductal Adenocarcinoma (PDAC) (Only for PDAC cohort) Further inclusion criteria apply.
Exclusion criteria
* Any prior irinotecan-based therapy in the metastatic setting. * Previous systemic anti-cancer therapy within the specified timeframe from the last dose intake to the first dose of trial treatment as follows: * Any non-investigational drug, including anti-angiogenic agents (bevacizumab or ramucirumab or aflibercept) and anti-EGFR antibodies (cetuximab or panitumumab), within 14 days. * Any investigational drug or other antibodies including immune checkpoint inhibitors, within 28 days. * Currently enrolled in another investigational device or drug trial. Patients who are in follow-up/observation for another clinical trial are eligible. * Radiation therapy within 4 weeks prior to start of treatment. However, palliative radiotherapy for symptomatic metastasis is allowed if completed within 2 weeks prior to start of treatment. * Any serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal (GI) tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator, would make the patient inappropriate for entry into the trial. * Known pathological condition of GI tract, liver and pancreas, excluding the disease under study, that may interfere with assessment of drug safety or may increase the risk of toxicity: * inflammatory bowel disease * chronic pancreatitis * other serious GI pathological conditions by judgment of the investigator e.g. autoimmune disease with GI involvement, unexplained active diarrhea CTCAE v5.0 grade ≥ 2. * Known history of human immunodeficiency virus (HIV) infection. * Any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable if done within 14 days before the informed consent date: * Positive results of hepatitis B surface (HBs) antigen * Presence of HBc antibody together with hepatitis B virus deoxyribonucleic acid (HBV-DNA) * Presence of hepatitis C ribonucleic acid (RNA) Further
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of the Maximum Tolerated Dose (MTD) of BI 905711 | From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the residual effect period (REP) (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days. | Maximum tolerated dose (MTD) was defined as the highest dose with less than 25% risk of the true dose-limiting toxicity (DLT) rate being equal or above 33% during the MTD evaluation period. The MTD was to be considered reached if one of the following criteria was fulfilled: the posterior probability of the true DLT rate in the target interval (0.16, 0.33) of the MTD was above 0.5, or at least 12 patients had been treated in Phase Ia, of which at least 6 at the MTD. |
| Number of Patients With Dose Limiting Toxicity (DLT) During MTD Evaluation | From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the REP (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days. | Number of patients with dose limiting toxicity (DLT) during MTD evaluation is presented. |
| Confirmed Objective Response (OR) | From the first administration of trial medication until the earliest of progressive disease (PD), death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, up to 54 weeks. | Confirmed objective response (OR) as assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for target lesions and assessed by MRI in patients with measurable disease, defined as the best overall response of complete response (CR) or partial response (PR), from the first administration of trial medication until the earliest of progressive disease (PD), death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. |
| Number of PDAC Patients With DLTs During the MTD Evaluation Period Assessed in the First 6 Patients | From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the REP (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days. | In safety run-in part of Pancreatic Ductal Adenocarcinoma (PDAC) cohort. Number of PDAC patients with DLTs during the MTD evaluation period assessed in the first 6 patients is presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From date of start of treatment to the date of disease progression or death, whichever is earlier as assessed by the investigator according to RECIST 1.1., up to 54 weeks. | Progression-Free Survival (PFS) defined from date of start of treatment to the date of disease progression or death, whichever is earlier as assessed by the investigator according to RECIST 1.1 is presented. |
| Maximum Percentage Change From Baseline in the Sum of Longest Target Lesion Diameters | At baseline and every 8 weeks (± 7 days) until progression or start of further treatment for disease, up to 54 weeks. | Radiological (CT Scan) tumor shrinkage, defined as the difference between the minimum post-baseline sum of longest diameters of target lesions and the baseline sum of longest diameters of the same set of target lesions according to RECIST 1.1. is presented. Negative values indicate a reduction in the sum of target lesion diameters and positive values indicate an increase. Median change from baseline was calculated for each patient and then summarized over all patients. |
| Duration of Objective Response (OR) | From the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented, up to 54 weeks. | The duration of OR is measured from the time measurement criteria are first met for complete response (CR)/ partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease (PD) is objectively documented (taking as reference for PD the smallest measurements recorded on study) according to RECIST 1.1. . |
| Disease Control | From the start of treatment until the earliest of PD, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy, up to 54 weeks. | Disease control, defined as complete response (CR), partial response (PR), or stable disease (SD) lasting at least 16 weeks according to RECIST 1.1 from the start of treatment until the earliest of PD, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy. |
| Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax) | At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1. | Maximum measured plasma concentration of BI 905711 during the first cycle (Cmax) in phase Ia is presented. |
| Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax) in Phase Ib | Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion. | Maximum measured plasma concentration of BI 905711 after multiple cycles (Cmax) in phase Ib is presented. |
| Area Under the Concentration-time Curve of BI 9057 During the First Treatment Cycle (AUC0-t2) in Phase Ib | At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1. | Area under the concentration-time curve of BI 9057 during the first treatment cycle (AUC0-t2) in phase Ib is presented. |
| Area Under the Concentration-time Curve of BI 9057 After Multiple Cycles (AUC0-t2) in Phase Ib | Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion. | Area under the concentration-time curve of BI 9057 after multiple cycles (AUC0-t2) in phase Ib is presented. |
| Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax) in Phase Ib | At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1. | Maximum measured plasma concentration of BI 905711 during the first cycle (Cmax) in phase Ib is presented. |
| Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax) | Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion. | Maximum measured plasma concentration of BI 905711 after multiple cycles (Cmax) in phase Ia is presented. |
| Area Under the Concentration-time Curve in Plasma of BI 905711 During the First Cycle (AUC0-336) | At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1. | Area under the concentration-time curve in plasma of BI 905711 during the first cycle (AUC0-336) in phase Ia is presented. |
| Area Under the Concentration Time-curve in Plasma of BI 905711 After Multiple Cycles (AUC0-336) | Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion. | Area under the concentration time-curve in plasma of BI 905711 after multiple cycles (AUC0-336) in phase Ia is presented. |
Countries
Belgium, China, France, Japan, United States
Participant flow
Recruitment details
The main objective of this phase Ia/Ib, open label, multicentre, dose escalation followed by expansion cohorts study was to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE), and to explore the pharmacokinetics, pharmacodynamics, safety and efficacy of BI 905711 in combination with FOLFIRI regimen plus bevacizumab in colorectal adenocarcinoma (CRC) patients.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| 0.6 mg/kg BI 905711 + FOLFIRI + Bevacizumab Patients with colorectal adenocarcinoma (CRC) received a single administration of 0.6 milligrams (mg) / kilograms (kg) of BI 905711 intravenously on Day 3 of each 14-day cycle. Patients also received FOLFIRI (irinotecan: 180 mg/squaremeters (m2) over 1.5 hours (hrs), leucovorin: 400 mg/m2 (in Japan: levoleucovorin: 200 mg/m2) over 2 hrs, fluorouracil: 400 mg/m2 bolus or 2400 mg/m2 46 hrs continuous infusion) in combination with bevacizumab, 5 mg/kg over 30 minutes (min) intravenously on Day 1 of each 14-day cycle. | 9 |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab Patients with colorectal adenocarcinoma (CRC) received a single administration of 1.2 mg/kg of BI 905711 intravenously on Day 3 of each 14-day cycle. Patients also received FOLFIRI (irinotecan: 180 mg/m2 over 1.5 hours (hrs), leucovorin: 400 mg/m2 (in Japan: levoleucovorin: 200 mg/m2) over 2 hrs, fluorouracil: 400 mg/m2 bolus or 2400 mg/m2 46 hrs continuous infusion) in combination with bevacizumab, 5 mg/kg over 30 minutes (min) intravenously on Day 1 of each 14-day cycle. | 3 |
| FOLFIRI + Bevacizumab Patients with colorectal adenocarcinoma (CRC) received FOLFIRI (irinotecan: 180 mg/m2 over 1.5 hours (hrs), leucovorin \[or levoleucovorin\]: 400 mg/m2 (in Japan: levoleucovorin: 200 mg/m2) over 2 hrs, fluorouracil: 400 mg/m2 bolus or 2400 mg/m2 46 hrs continuous infusion) in combination with bevacizumab, 5 mg/kg over 30 minutes (min) intravenously on Day 1 of each 14-day cycle. | 1 |
| Total | 13 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 | 0 |
| Overall Study | clinical disease progression | 3 | 1 | 0 |
| Overall Study | objective disease progression | 4 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | 0.6 mg/kg BI 905711 + FOLFIRI + Bevacizumab | 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | FOLFIRI + Bevacizumab | Total |
|---|---|---|---|---|
| Age, Continuous | 54.4 Years STANDARD_DEVIATION 10.7 | 60.3 Years STANDARD_DEVIATION 11.2 | NA Years | 54.6 Years STANDARD_DEVIATION 11.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 3 Participants | NA Participants | NA Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) Asian | 5 Participants | 1 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 2 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | NA Participants | NA Participants |
| Race (NIH/OMB) White | 4 Participants | 0 Participants | NA Participants | NA Participants |
| Sex: Female, Male Female | 5 Participants | 1 Participants | NA Participants | NA Participants |
| Sex: Female, Male Male | 4 Participants | 2 Participants | NA Participants | NA Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 9 | 2 / 3 | 0 / 1 |
| other Total, other adverse events | 9 / 9 | 3 / 3 | 1 / 1 |
| serious Total, serious adverse events | 4 / 9 | 2 / 3 | 0 / 1 |
Outcome results
Primary
Confirmed Objective Response (OR)
Confirmed objective response (OR) as assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for target lesions and assessed by MRI in patients with measurable disease, defined as the best overall response of complete response (CR) or partial response (PR), from the first administration of trial medication until the earliest of progressive disease (PD), death or last evaluable tumor assessment before start of subsequent anti-cancer therapy.
Time frame: From the first administration of trial medication until the earliest of progressive disease (PD), death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, up to 54 weeks.
Population: Treated set (TS): This included all subjects who were dispensed study medication and were documented to have been treated with at least one dose of BI 905711 or chemotherapy. This TS was used for both safety and efficacy analyses.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Confirmed Objective Response (OR) | 0 Participants |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Confirmed Objective Response (OR) | 0 Participants |
| FOLFIRI + Bevacizumab | Confirmed Objective Response (OR) | 0 Participants |
Primary
Determination of the Maximum Tolerated Dose (MTD) of BI 905711
Maximum tolerated dose (MTD) was defined as the highest dose with less than 25% risk of the true dose-limiting toxicity (DLT) rate being equal or above 33% during the MTD evaluation period. The MTD was to be considered reached if one of the following criteria was fulfilled: the posterior probability of the true DLT rate in the target interval (0.16, 0.33) of the MTD was above 0.5, or at least 12 patients had been treated in Phase Ia, of which at least 6 at the MTD.
Time frame: From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the residual effect period (REP) (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days.
Population: Maximum tolerated dose evaluation set (MTDS): This included all patients in the TS who were not replaced for the MTD determination. The MTDS was used for the primary analyses of dose-limiting toxicities (DLTs) and MTD determination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Determination of the Maximum Tolerated Dose (MTD) of BI 905711 | NA milligram / kilogram (mg/kg) |
Primary
Number of Patients With Dose Limiting Toxicity (DLT) During MTD Evaluation
Number of patients with dose limiting toxicity (DLT) during MTD evaluation is presented.
Time frame: From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the REP (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days.
Population: Maximum tolerated dose evaluation set (MTDS): This included all patients in the TS who were not replaced for the MTD determination. The MTDS was used for the primary analyses of dose-limiting toxicities (DLTs) and MTD determination. Only treated patients from the dose escalation part were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Number of Patients With Dose Limiting Toxicity (DLT) During MTD Evaluation | 0 Participants |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Number of Patients With Dose Limiting Toxicity (DLT) During MTD Evaluation | 2 Participants |
Primary
Number of PDAC Patients With DLTs During the MTD Evaluation Period Assessed in the First 6 Patients
In safety run-in part of Pancreatic Ductal Adenocarcinoma (PDAC) cohort. Number of PDAC patients with DLTs during the MTD evaluation period assessed in the first 6 patients is presented.
Time frame: From cycle 1 Day 1 until the day before cycle 3 Day 1 (2 14-day treatment cycles), or end of the REP (30 days + 5 days) in case of discontinuation before start of cycle 3, up to 35 days.
Population: Due to the stopping criteria in the protocol of the clinical development of BI 905711, recruitment in this trial was prematurely discontinued during the Phase Ib expansion phase and no PDAC patients were enrolled.
Secondary
Area Under the Concentration Time-curve in Plasma of BI 905711 After Multiple Cycles (AUC0-336)
Area under the concentration time-curve in plasma of BI 905711 after multiple cycles (AUC0-336) in phase Ia is presented.
Time frame: Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion.
Population: Pharmacokinetic parameter analysis set (PKS): This included all subjects in the treated set (TS) who provided at least one PK endpoint and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Area Under the Concentration Time-curve in Plasma of BI 905711 After Multiple Cycles (AUC0-336) | 352000 hours * nanograms/milliliter (h*ng/ml) | Geometric Coefficient of Variation 73.3 |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Area Under the Concentration Time-curve in Plasma of BI 905711 After Multiple Cycles (AUC0-336) | 565000 hours * nanograms/milliliter (h*ng/ml) | Geometric Coefficient of Variation 29 |
Secondary
Area Under the Concentration-time Curve in Plasma of BI 905711 During the First Cycle (AUC0-336)
Area under the concentration-time curve in plasma of BI 905711 during the first cycle (AUC0-336) in phase Ia is presented.
Time frame: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1.
Population: Pharmacokinetic parameter analysis set (PKS): This included all subjects in the treated set (TS) who provided at least one PK endpoint and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Area Under the Concentration-time Curve in Plasma of BI 905711 During the First Cycle (AUC0-336) | 372000 hours * nanograms/milliliter (h*ng/ml) | Geometric Coefficient of Variation 53.4 |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Area Under the Concentration-time Curve in Plasma of BI 905711 During the First Cycle (AUC0-336) | 702000 hours * nanograms/milliliter (h*ng/ml) | Geometric Coefficient of Variation 49.4 |
Secondary
Area Under the Concentration-time Curve of BI 9057 After Multiple Cycles (AUC0-t2) in Phase Ib
Area under the concentration-time curve of BI 9057 after multiple cycles (AUC0-t2) in phase Ib is presented.
Time frame: Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion.
Population: Due to the termination of the clinical development of BI 905711, recruitment in this trial was prematurely discontinued during the Phase Ib expansion phase and no PDAC patients were enrolled.
Secondary
Area Under the Concentration-time Curve of BI 9057 During the First Treatment Cycle (AUC0-t2) in Phase Ib
Area under the concentration-time curve of BI 9057 during the first treatment cycle (AUC0-t2) in phase Ib is presented.
Time frame: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1.
Population: Due to the termination of the clinical development of BI 905711, recruitment in this trial was prematurely discontinued during the Phase Ib expansion phase and no PDAC patients were enrolled.
Secondary
Disease Control
Disease control, defined as complete response (CR), partial response (PR), or stable disease (SD) lasting at least 16 weeks according to RECIST 1.1 from the start of treatment until the earliest of PD, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy.
Time frame: From the start of treatment until the earliest of PD, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy, up to 54 weeks.
Population: Treated set (TS): This included all subjects who were dispensed study medication and were documented to have been treated with at least one dose of BI 905711 or chemotherapy. This TS was used for both safety and efficacy analyses. Only patients with disease control were included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Disease Control | 248.0 days |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Disease Control | 220.5 days |
Secondary
Duration of Objective Response (OR)
The duration of OR is measured from the time measurement criteria are first met for complete response (CR)/ partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease (PD) is objectively documented (taking as reference for PD the smallest measurements recorded on study) according to RECIST 1.1. .
Time frame: From the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented, up to 54 weeks.
Population: Treated set (TS): This included all subjects who were dispensed study medication and were documented to have been treated with at least one dose of BI 905711 or chemotherapy. This TS was used for both safety and efficacy analyses. Only patients with objective response were included.
Secondary
Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax)
Maximum measured plasma concentration of BI 905711 after multiple cycles (Cmax) in phase Ia is presented.
Time frame: Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion.
Population: Pharmacokinetic parameter analysis set (PKS): This included all subjects in the treated set (TS) who provided at least one PK endpoint and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax) | 6660 nanograms/milliliter (ng/ml) | Geometric Coefficient of Variation 25.4 |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax) | 9280 nanograms/milliliter (ng/ml) | Geometric Coefficient of Variation 23.8 |
Secondary
Maximum Measured Plasma Concentration of BI 905711 After Multiple Cycles (Cmax) in Phase Ib
Maximum measured plasma concentration of BI 905711 after multiple cycles (Cmax) in phase Ib is presented.
Time frame: Cycle 3: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion.
Population: Due to the termination of the clinical development of BI 905711, recruitment in this trial was prematurely discontinued during the Phase Ib expansion phase and no PDAC patients were enrolled.
Secondary
Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax)
Maximum measured plasma concentration of BI 905711 during the first cycle (Cmax) in phase Ia is presented.
Time frame: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1.
Population: Pharmacokinetic parameter analysis set (PKS): This included all subjects in the treated set (TS) who provided at least one PK endpoint and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax) | 6100 nanograms / milliliter (ng/ml) | Geometric Coefficient of Variation 36.6 |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax) | 11500 nanograms / milliliter (ng/ml) | Geometric Coefficient of Variation 23.9 |
Secondary
Maximum Measured Plasma Concentration of BI 905711 During the First Cycle (Cmax) in Phase Ib
Maximum measured plasma concentration of BI 905711 during the first cycle (Cmax) in phase Ib is presented.
Time frame: At 5 minutes (min) before start of BI 905711 infusion and at 30 min, 7 hours (hrs), 24 hrs, 48 hrs, 168 hrs and 336 hrs after BI 905711 infusion in cycle 1.
Population: Due to the termination of the clinical development of BI 905711, recruitment in this trial was prematurely discontinued during the Phase Ib expansion phase and no PDAC patients were enrolled.
Secondary
Maximum Percentage Change From Baseline in the Sum of Longest Target Lesion Diameters
Radiological (CT Scan) tumor shrinkage, defined as the difference between the minimum post-baseline sum of longest diameters of target lesions and the baseline sum of longest diameters of the same set of target lesions according to RECIST 1.1. is presented. Negative values indicate a reduction in the sum of target lesion diameters and positive values indicate an increase. Median change from baseline was calculated for each patient and then summarized over all patients.
Time frame: At baseline and every 8 weeks (± 7 days) until progression or start of further treatment for disease, up to 54 weeks.
Population: Treated set (TS): This included all subjects who were dispensed study medication and were documented to have been treated with at least one dose of BI 905711 or chemotherapy. This TS was used for both safety and efficacy analyses. Only patients with tumor diameter measurements were included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Maximum Percentage Change From Baseline in the Sum of Longest Target Lesion Diameters | -13.9 Percentage change in tumor diameter |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Maximum Percentage Change From Baseline in the Sum of Longest Target Lesion Diameters | 4.5 Percentage change in tumor diameter |
Secondary
Progression Free Survival (PFS)
Progression-Free Survival (PFS) defined from date of start of treatment to the date of disease progression or death, whichever is earlier as assessed by the investigator according to RECIST 1.1 is presented.
Time frame: From date of start of treatment to the date of disease progression or death, whichever is earlier as assessed by the investigator according to RECIST 1.1., up to 54 weeks.
Population: Treated set (TS): This included all subjects who were dispensed study medication and were documented to have been treated with at least one dose of BI 905711 or chemotherapy. This TS was used for both safety and efficacy analyses.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BI 905711 + FOLFIRI + Bevacizumab | Progression Free Survival (PFS) | 31.00 weeks |
| 1.2 mg/kg BI 905711 + FOLFIRI + Bevacizumab | Progression Free Survival (PFS) | 29.57 weeks |
| FOLFIRI + Bevacizumab | Progression Free Survival (PFS) | NA weeks |